Atrial appendage occluder sales will strengthen through 2036, anchored by endocardial devices at a 57.6% share, driven by demand for catheter-based LAA closure enabling percutaneous implantation. Atrial fibrillation associated stroke prevention leads with a 49.3% share. The market is set to reach USD 1.2 billion by 2026-end and USD 2.1 billion by 2036.